Animal Sci. Prods. v. Hebei Welcome Pharma. Co. Ltd.

8 F.4th 136
Court of Appeals for the Second Circuit·Decided August 10, 2021·No. 13-4791-cv·Published·Cited by 10 cases

Opinion

No. 13-4791-cv Animal Sci. Prods. v. Hebei Welcome Pharma. Co. Ltd.

In the

United States Court of Appeals for the Second Circuit

August Term, 2020

No. 13-4791-cv

ANIMAL SCIENCE PRODUCTS, INC., THE RANIS COMPANY, INC., Plaintiffs-Appellees,

v.

HEBEI WELCOME PHARMACEUTICAL CO. LTD., NORTH CHINA PHARMACEUTICAL GROUP CORPORATION,

Defendants-Appellants.

Appeal from the United States District Court for the Southern District of New York.

No. 1:06-md-1738 — Brian M. Cogan, Judge.

ARGUED: MARCH 17, 2021

DECIDED: AUGUST 10, 2021

Before: CABRANES, WESLEY, and NARDINI, Circuit Judges.

Animal Science Products, Inc. and The Ranis Company, Inc. (the “plaintiffs”), American purchasers of bulk Vitamin C, brought this class action

alleging that four Chinese exporters of Vitamin C conspired to inflate prices and restrict supply in violation of the Sherman Act, 15 U.S.C. § 1, and the Clayton Act, 15 U.S.C. §§ 4, 16. The United States District Court for the Southern District of New York (Trager, J.) denied the defendants’ motion to dismiss on the basis of the act of state doctrine, foreign sovereign compulsion, and international comity. The district court (Cogan, J.) subsequently denied the defendants’ motion for summary judgment on the same grounds, and the case proceeded to trial. All defendants settled other than Hebei Welcome Pharmaceutical Co. Ltd. (“Hebei”) and its parent company North China Pharmaceutical Group Corp (“NCPG”). Following a jury verdict of liability, the district court entered a trebled damages award of $147,831,471.03, plus interest, and permanently enjoined Hebei and NCPG from future anti-competitive behavior. The district court then denied Hebei and NCPG’s renewed motion for judgment as a matter of law.

In this case’s first trip to our Court, we reversed. We held that the district court was bound to defer to the facially reasonable explanation of Chinese law submitted by the Ministry of Commerce of the People’s Republic of China (the “Ministry”). According to the Ministry’s explanation, Chinese law required the defendants to undertake the anticompetitive conduct at issue, and—accepting this explanation as reasonable under the circumstances—we concluded that such a “true conflict” between China’s regulatory scheme and U.S. antitrust laws, in combination with other international comity factors, mandated dismissal of the plaintiffs’ suit. The Supreme Court reversed, holding that we afforded too much deference to the Ministry’s submissions, and remanded for us to carefully consider but not conclusively defer to the Ministry’s views pursuant to Rule 44.1 of the Federal Rules of Civil Procedure.

Applying the Supreme Court’s instructions, we conclude once again that this case should be dismissed on international comity grounds. Giving careful consideration but not conclusive deference to the Ministry’s views, we read the relevant Chinese regulations—as illuminated by contemporaneous administrative documents and industry reports—to have required the defendants to collude on Vitamin C export prices and quantities as part and parcel of China’s export regime for Vitamin C. Balancing this true conflict between U.S. and Chinese law together

with other established principles of international comity, we decline to construe U.S. antitrust law to reach the defendants’ conduct. Accordingly, we REVERSE and REMAND with instructions to dismiss the case. Judge WESLEY dissents in a separate opinion.

WILLIAM A. ISAACSON (Michael D. Hausfeld, Brian A.

Ratner, Melinda R. Coolidge, James T. Southwick, Shawn L. Raymond, Katherine Kunz, Brent W. Landau, on the brief), BOIES, SCHILLER & FLEXNER LLP, Washington, DC, for Plaintiffs-Appellees.

JONATHAN M. JACOBSON (Daniel P. Weick, Justin A.

Cohen, Scott A. Sher, Bradley T. Tennis, on the brief), WILSON SONSINI GOODRICH & ROSATI, P.C., New York, New York, for Defendants-Appellants.

CARTER G. PHILLIPS (Joel M. Mitnick, Kwaku A.

Akowuah, on the brief), SIDLEY AUSTIN LLP, Washington, DC, for Amicus Curiae Ministry of Commerce of the People’s Republic of China.

WILLIAM J. NARDINI, Circuit Judge:

We consider this appeal, which arises from an antitrust action brought against Defendants-Appellants Hebei Welcome Pharmaceutical Co. Ltd. (“Hebei”), North China Pharmaceutical Group Corporation (“NCPG”), and other entities incorporated under the laws of the People’s Republic of China (“PRC” or

“China”) (together, “Defendants-Appellants”), on remand from the Supreme Court. See Animal Sci. Prods., Inc. v. Hebei Welcome Pharm. Co., 138 S. Ct. 1865 (2018). Plaintiffs-Appellees Animal Science Products, Inc. and The Ranis Company, Inc. (together, “plaintiffs”), are U.S. purchasers of Vitamin C that allege Defendants- Appellants and others conspired to fix the price and supply of Vitamin C sold to U.S. companies on the international market in violation of Section 1 of the Sherman Act, 15 U.S.C. § 1, and Sections 4 and 16 of the Clayton Act, 15 U.S.C. §§ 4, 16.

This antitrust case is unusual in that the parties before us generally agree that the alleged anticompetitive conduct occurred. The dispute centers instead on “whether Chinese law required the Chinese sellers’ conduct.” Animal Sci. Prods., 138 S. Ct. at 1875. Thus, we must decide whether Chinese law made it impossible for the Defendants-Appellants to comply with U.S. antitrust law, such that a so- called “true conflict” exists. This determination is critical because the existence of a true conflict, balanced in combination with other principles of international comity, may weigh against construing U.S. antitrust law to reach anticompetitive conduct occurring abroad.

We ultimately conclude that Chinese law required Defendants-Appellants to engage in price-fixing of Vitamin C sold on the international market. Defendants-Appellants thus could not comply with both Chinese law and U.S. antitrust law. In light of this true conflict, we apply the remaining principles of international comity to balance the United States’ interest in the enforcement of its antitrust laws abroad against the international comity concerns implicated when those laws conflict with the laws of China. We conclude that principles of international comity required the district court to dismiss this action. We therefore REVERSE the judgment and REMAND with instructions to DISMISS the complaint with prejudice.

I. BACKGROUND For more than half a century, China has been a leading producer and exporter of Vitamin C. 1 In the 1970s, as China began to move into the competitive international economy under the general direction of the Communist Party of

1 We set forth here only those facts necessary to resolve the issues on appeal.

China, the Chinese government implemented various export controls to gain a competitive edge over other producers of Vitamin C on the international market. In the intervening years, the Chinese government continued to develop policies to retain its domestic producers’ competitive advantage. In the 1990s, for example, following a price war between producers in China, the Chinese government facilitated industry-wide consolidation and implemented regulations to control the prices of Vitamin C exports. By 2001, Chinese suppliers had captured 60% of the global Vitamin C market.

Several years later, in 2005, plaintiffs filed this antitrust action. The original complaint named four defendants, all of which are entities incorporated under the laws of China: Hebei, Jiangsu Jiangshan Pharmaceutical Co. Ltd. (“Jiangshan”), Northeast Pharmaceutical Group Co. Ltd. (“Northeast”), and Weisheng

Free access — add to your briefcase to read the full text and ask questions with AI

Animal Sci. Prods. v. Hebei Welcome Pharma. Co. Ltd., 8 F.4th 136 (2d Cir. 2021).

8 F.4th 136 (Animal Sci. Prods. v. Hebei Welcome Pharma. Co. Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related